Nektar Therapeutics (NKTR) stock
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$30.20−2.34 (-7.19%)
Close on Nov 20, 2026Market cap $1.03BP/E –Yield –
Nektar Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Nektar Therapeutics's gross profit for the twelve months ending Dec 31, 2025 was $55.23M, down 18.5% year over year. For fiscal 2025 it was $55.23M, down 18.5% from the year before. Over ten years it grew -11.9% a year on average. The highest annual figure on record is $1.17B in fiscal 2018.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.23M | -18.5% |
| FY2024 | Dec 31, 2024 | $67.74M | +20.2% |
| FY2023 | Dec 31, 2023 | $56.35M | -20.0% |
| FY2022 | Dec 31, 2022 | $70.42M | -8.6% |
| FY2021 | Dec 31, 2021 | $77.01M | -42.3% |
| FY2020 | Dec 31, 2020 | $133.44M | +43.1% |
| FY2019 | Dec 31, 2019 | $93.24M | -92.0% |
| FY2018 | Dec 31, 2018 | $1.17B | +321.7% |
| FY2017 | Dec 31, 2017 | $277.16M | +105.0% |
| FY2016 | Dec 31, 2016 | $135.22M | -31.2% |
| FY2015 | Dec 31, 2015 | $196.68M | +14.2% |
| FY2014 | Dec 31, 2014 | $172.17M | +55.9% |
| FY2013 | Dec 31, 2013 | $110.41M | +117.5% |
| FY2012 | Dec 31, 2012 | $50.76M | +2.4% |
| FY2011 | Dec 31, 2011 | $49.59M | -62.8% |
| FY2010 | Dec 31, 2010 | $133.37M | +225.4% |
| FY2009 | Dec 31, 2009 | $40.98M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $21.81M | +2.9% |
| Q3 FY2025 | Sep 30, 2025 | $11.79M | -40.1% |
| Q2 FY2025 | Jun 30, 2025 | $11.18M | -18.7% |
| Q1 FY2025 | Mar 31, 2025 | $10.46M | -20.2% |
| Q4 FY2024 | Dec 31, 2024 | $21.20M | +27.7% |
| Q3 FY2024 | Sep 30, 2024 | $19.69M | +68.1% |
| Q2 FY2024 | Jun 30, 2024 | $13.75M | +1.8% |
| Q1 FY2024 | Mar 31, 2024 | $13.11M | -9.8% |
| Q4 FY2023 | Dec 31, 2023 | $16.60M | +5.1% |
| Q3 FY2023 | Sep 30, 2023 | $11.71M | -37.2% |
| Q2 FY2023 | Jun 30, 2023 | $13.51M | -18.0% |
| Q1 FY2023 | Mar 31, 2023 | $14.53M | -25.5% |
| Q4 FY2022 | Dec 31, 2022 | $15.79M | -16.2% |
| Q3 FY2022 | Sep 30, 2022 | $18.65M | -4.9% |
| Q2 FY2022 | Jun 30, 2022 | $16.47M | -20.3% |
| Q1 FY2022 | Mar 31, 2022 | $19.51M | +9.0% |
| Q4 FY2021 | Dec 31, 2021 | $18.85M | -1.5% |
| Q3 FY2021 | Sep 30, 2021 | $19.61M | -19.8% |
| Q2 FY2021 | Jun 30, 2021 | $20.66M | -52.0% |
| Q1 FY2021 | Mar 31, 2021 | $17.89M | -61.7% |
| Q4 FY2020 | Dec 31, 2020 | $19.14M | -31.3% |
| Q3 FY2020 | Sep 30, 2020 | $24.46M | +0.7% |
| Q2 FY2020 | Jun 30, 2020 | $43.07M | +135.4% |
| Q1 FY2020 | Mar 31, 2020 | $46.76M | +105.3% |
| Q4 FY2019 | Dec 31, 2019 | $27.87M | -13.9% |
| Q3 FY2019 | Sep 30, 2019 | $24.29M | +5.7% |
| Q2 FY2019 | Jun 30, 2019 | $18.30M | -98.3% |
| Q1 FY2019 | Mar 31, 2019 | $22.78M | -27.4% |
| Q4 FY2018 | Dec 31, 2018 | $32.37M | -62.2% |
| Q3 FY2018 | Sep 30, 2018 | $22.98M | -84.4% |
| Q2 FY2018 | Jun 30, 2018 | $1.08B | +4127.3% |
| Q1 FY2018 | Mar 31, 2018 | $31.37M | +68.7% |
| Q4 FY2017 | Dec 31, 2017 | $85.71M | +177.9% |
| Q3 FY2017 | Sep 30, 2017 | $147.25M | +402.5% |
| Q2 FY2017 | Jun 30, 2017 | $25.60M | +2.2% |
| Q1 FY2017 | Mar 31, 2017 | $18.60M | – |
| Q4 FY2016 | Dec 31, 2016 | $30.85M | – |
| Q3 FY2016 | Sep 30, 2016 | $29.30M | – |
| Q2 FY2016 | Jun 30, 2016 | $25.06M | – |
See a number that looks wrong?